옵션 체인은 다양한 행사가격과 만기일에 대한 ImmunityBio의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 ImmunityBio에 대한 시장 심리를 평가합니다..

ImmunityBio (NASDAQ:IBRX) 주식, 옵션 체인

IMMUNITYBIO INC

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

San,Jose,,California,Us,-,February,14,,2025:,Archer,Brand

Equities

Mid Cap

News

Movers

ACHR

DBRG

DGNX

IBRX

LUNR

OKLO

지난주 최고의 성과를 거둔 중형주는 다음과 같다. 풋락커, 아처 에비에이션, 디지털브릿지, 뉴스케일 파워, 디지넥스, 이뮤니티바이오, 오클로, 인튜이티브 머신스

풋락커·아처에비에이션 등 지난주 급등한 중형주 8종목 (5월 12~16일)

Quantum Computing

Trading Ideas

ALHC

BPMC

COMP

HEES

IONQ

MSFT

NVDA

OPCH

SEMR

1월 13일부터 17일까지 지난주에 최고의 실적을 거둔 중형주 8종목은 다음과 같다 .H&amp;E 이큅먼트 SEM러시 컴퍼스 블루프린트 얼라인먼트 옵션 케어 이뮤니티바이오 아이온큐

아이온큐, H&amp;E 이큅먼트, 이뮤니티바이오 등 지난주 급등한 중형주 (1월 13일~17일)

$BTC

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

ImmunityBio Inc

Management

NVNO

enVVeno Medical Appoints Jennifer Bright As CFO

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/16/final-trades-dell-boeing-unitedhealth-and-qxo.html">Halftime Report Final Trades</a>,&#8221; Kevin Simpson, Capital Wealth Planning founder and CIO, mentioned the huge week for The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).
As per recent news, Boeing disclosed on May 13 that Saudi Arabia-based AviLease placed its first direct order for the purchase of 20 737-8 jets, along with options for an additional 10 aircraft.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a> 
Bryn Talkington, managing partner at Requisite Capital Management, named Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), which is scheduled to report quarterly <a href="https://www.benzinga.com/quote/DELL/earnings">earnings on May 29</a>.
Analysts expect the company to report quarterly earnings at $1.68 per share, up from $1.27 per share in the year-ago period. Dell projects to report quarterly revenue of $23.17 billion, compared to $22.24 billion a year earlier.
Rob Sechan, CEO of NewEdge Wealth, picked UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) as his final trade.
UnitedHealth shares closed higher on Friday, rebounding after falling Thursday on a report indicating the company is under investigation by the US Department of Justice for possible Medicare fraud. The company said it has not been notified by the Department of Justice of the supposed criminal investigation reported.
Stephen Weiss, Chief Investment Officer and Managing Partner of Short Hills Capital Partners, named QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) as his final trade.
Lending support to his choice, QXO, on May 8, posted better-than-expected results for the first quarter.
Price Action:
<ul class="wp-block-list">
<li>Dell shares gained 3% to close at $114.19 on Friday.</li>
<li>UnitedHealth Group shares rose 6.4% to settle at $291.91 during Friday's session.</li>
<li>Boeing shares fell 0.2% to close at $205.82 on Friday.</li>
<li>QXO shares rose 3.2% to $16.79 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45466849/top-3-consumer-stocks-that-may-fall-off-a-cliff-in-q2">Top 3 Consumer Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

DELL

Boeing, Dell, QXO And A Health Care Stock On CNBC's 'Final Trades'

Former PIMCO CEO and current Allianz&#8217;s chief economic adviser, Mohamed El-Erian, has suggested that the era of U.S. exceptionalism is on pause, not conclusively over, amid President Donald Trump&#8216;s tariffs and economic uncertainty.
What Happened: El-Erian expressed his views on the current state of U.S. exceptionalism in a phone interview with&nbsp;<a href="https://www.marketwatch.com/story/el-erian-says-the-era-of-u-s-exceptionalism-is-on-pause-4b3d9638">MarketWatch</a>&nbsp;on Monday. He believes it&#8217;s premature to conclude if the damage caused by tariff wars and economic uncertainty is permanent. However, he weighed in that the tariff wars and the resulting uncertainty must come to an end.
&#8220;It&#8217;s too early to say if the damage inflicted is irreversible, stated El-Erian.
Although he holds positions at the University of Cambridge, El-Erian isn't inherently opposed to tariffs. He believes limited tariffs, used for a limited period, can be beneficial if they help create a more equitable trading system.
El-Erian, however, criticized the multiple objectives of the trade wars, such as reducing taxes while protecting domestic industries. He pointed out the potential for these goals to clash and cause unintended harm.&nbsp;&#8220;Some of these objectives are contradictory&#8230;and &#8220;liable to inflict collateral damage,&#8221; cautioned the economist. 
He also raised the possibility that other countries might impose tariffs on China or on one another, resulting in structurally higher prices worldwide.
El-Erian approached the recent departure of overseas investors from U.S. asset markets with caution in his assessment. He pointed out that the world was heavily invested in U.S. assets when tariff tensions started, largely due to beliefs in U.S. exceptionalism and innovation. He maintains that America's large economy and well-established institutions will always warrant a long-term positive outlook.
The economist also weighed in on Moody&#8217;s recent downgrade of the U.S. debt rating, calling it historic while anticipating that its impact on the market would probably be limited.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/management/25/05/45486759/dairy-queen-ceo-reveals-warren-buffetts-shocking-first-move-in-job-interview-ill-never-forget-the" target="_blank" rel="noreferrer noopener">Dairy Queen CEO Reveals Warren Buffett&#8217;s Shocking First Move in Job Interview: &#8216;I&#8217;ll Never Forget The Day&#8230;&#8217;</a>
Why It Matters: El-Erian&#8217;s comments come at a time when the U.S. economy is grappling with the impact of trade wars and economic uncertainty. Earlier this month, El-Erian highlighted potential "adverse implications" for domestic industries following a surprisingly strong surge in China's exports for April, despite a <a href="https://www.benzinga.com/government/regulations/25/05/45311562/mohamed-el-erian-flags-adverse-implications-for-domestic-industries-as-chinas-exports-rise-8-despite-21-drop-in-us-shipments">significant </a>drop in sales to the U.S.
Furthermore, El-Erian recently drew parallels between chapters of economic history and Federal Reserve Chair Jerome Powell&#8217;s concerns about more frequent and potentially more persistent supply shocks. He noted that such shocks would <a href="https://www.benzinga.com/markets/25/05/45459474/sounds-familiar-mohamed-el-erian-calls-out-powells-deja-vu-on-supply-shocks-economist-draws-historic-parallels-on-fed-chairs-latest-message">pose </a>a "difficult challenge for the economy and for central banks.&#8221;
These observations underscore the complexity and uncertainty surrounding the current economic landscape and the potential challenges that lie ahead for the U.S. economy. Notably, on Sunday, Treasury Secretary Scott Bessent <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">warned </a>that U.S. tariffs could quickly return to their "reciprocal" levels from "Liberation Day" if countries do not reach trade agreements within the existing 90-day timeframe.
The S&amp;P 500 has made a historic turnaround, climbing 19.57% from its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45445101/rout-to-rally-sp-500-stages-fastest-flip-in-market-history-with-22-comeback">lows </a>on April 8, while the NASDAQ surged 25.38%. Charlie Bilello, founder of Compound Capital Advisors, described it as "one of the biggest short-term comebacks in market history."
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45485070/the-stock-market-is-shooting-through-the-roof-says-dave-ramsey-but-claims-the-medias-silent-they-want-you-ad" target="_blank" rel="noreferrer noopener">&#8216;The Stock Market Is Shooting Through The Roof,&#8217; Says Dave Ramsey. But Claims The Media&#8217;s Silent—&#8217;They Want You Addicted To Fear&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mohamed El-Erian Says Era Of US Exceptionalism Is Paused, But Not Over Yet: 'Too Early To Say If The Damage Inflicted Is Irreversible'

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and lowers the price target from $220 to $215.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Lowers Price Target to $215

WIIM

Mobilicom shares are trading higher following Q1 reported financial results.

SKYE

Skye Bioscience shares are trading higher after the company announced a collaboration with Arecor to improve dosing and patient compliance.

Watching JPMorgan; During Investor Day, CFO Reportedly Says FY25 Net Interest Income Might End Up A Little Better, Maybe By $1B; Says Inflation And Fiscal Deficit May Constrain Available Policy Responses

QNTM

Quantum Biopharma shares are trading higher after the company announced it purchased $1 million worth of bitcoin and other cryptocurrencies as part of its digital asset strategic efforts.

United Homes Group, Inc. (the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uhg#NASDAQ">UHG</a>) today announced the appointment of John G. (Jack) Micenko, Jr., as Chief Executive Officer of the Company and Jeremy Pyle as co-Chief Operating Officer of the
United Homes Group, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) today announced the appointment of John G. (Jack) Micenko, Jr., as Chief Executive Officer of the Company and Jeremy Pyle as co-Chief Operating Officer of the Company, and simultaneously therewith announced that its Board of Directors has appointed a special committee comprised solely of independent directors and initiated a review of strategic alternatives in order to explore ways to maximize shareholder value. The review will include a range of potential strategic alternatives, including a sale of the Company, a sale of assets, and a refinancing of existing indebtedness, among others. Mr. Micenko succeeds James M. (Jamie) Pirrello, who previously served as the Company's Interim Chief Executive Officer, and will continue to serve as a member of the Company's board of directors.

Penny Stocks

United Homes Group Appoints Jack Micenko As CEO And Jeremy Pyle As Co-COO, Replaces Interim CEO Jamie Pirrello, And Simultaneously Launches Strategic Alternatives Review Including Potential Sale, Asset Divestitures, Or Debt Refinancing To Maximize Shareholder Value

On May 16, 2025, a purported class action lawsuit was filed in the U.S. District Court for the Eastern District of Virginia against us, Michael J. Saylor, Phong Le, and Andrew Kang, alleging violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 thereunder, and Section 20(a) of the Exchange Act. The plaintiff, Anas Hamza, purports to assert claims on behalf of a purported class of investors, for a period running from April 30, 2024 to April 4, 2025, alleging that the named defendants made false and/or misleading statements with respect to and/or failed to disclose information with respect to the anticipated profitability of our bitcoin-focused investment strategy and treasury operations, and the various risks associated with bitcoin's volatility and the magnitude of the losses.
we could recognize following our adoption of Accounting Standards Update No. 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. The complaint seeks unspecified damages to the class, interest, attorneys' fees, costs, and other relief. We intend to vigorously defend against these claims. At this time, we cannot predict the outcome, or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.

Legal

MSTR

Class Action Lawsuit Filed Against MicroStrategy, Executives Including Michael Saylor, Alleging Securities Violations Over Misleading Statements On Bitcoin Strategy, Risks, and Losses Tied to New Crypto Accounting Standards, With Claims Covering April 2024 to April 2025

FRSX

Foresight Autonomous Signs Development And Commercialization Agreement With Zhejiang Streamrail Intelligent Control Technology Co To Integrate And Commercialize Its Products For Streamrail's Customers, Focusing On Urban Trams And Metro Trains; Current Project's Revenue Potential estimated Up To $12M By 2029

In a recent episode of The Ramsey Show, published on Sunday, Dave Ramsey fielded a call from a woman whose husband secretly wiped out nearly all of their retirement savings in a cryptocurrency scam.
What Happened: The 57-year-old caller explained that her 58-year-old husband had drained his 401(k) without her knowledge and invested the money in what turned out to be a crypto scam tied to a company in Hong Kong. 
Initially, he claimed it was just $30,000. But after months of evasion, the truth came out: he had lost $270,000—virtually their entire retirement fund. To complicate matters, the woman is battling cancer and had left her job due to side effects from her medication. With their home paid off and no debt, they were otherwise in a solid financial position—until this blow.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Husband Lost $270,000 Of Our 401(k) In A Scam" width="500" height="281" src="https://www.youtube.com/embed/YwLNqhEA1yU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
See Also: <a href="https://www.benzinga.com/news/25/05/45489464/steve-ballmer-once-said-this-about-being-a-billionaire-who-ever-thinks-theyre-going-to-have-enough-money-to-own-a-basketball-team-admitted-he-was-fundamentally-changed-by-wealth">Steve Ballmer Once Said This About Being A Billionaire: &#8216;Who&#8230;Ever Thinks They&#8217;re Going To Have Enough Money To Own A Basketball Team?,&#8217; Admitted He Was &#8216;Fundamentally Changed&#8217; By Wealth And Power</a>
Why It Matters: Ramsey's assessment was blunt: "This is more than just a dumb financial move—this is a betrayal," he told the caller. He said: "He not only did something stupid—he lied about it at length." 
He continued, "I'm not telling you to leave him. I am telling you, though, if he ever does something like this again, you should." Ramsey also addressed the couple's next steps. "You're going to have to work ten more years, save everything you can, and rebuild from scratch," he said. 
"There's no miracle investment. That's how you fix this."
On his show, Ramsey has highlighted the importance of 401(k)s multiple times. To a woman whose <a href="https://www.benzinga.com/news/25/05/45335414/dave-ramsey-tells-woman-whose-boyfriend-thinks-401ks-are-a-scam-dont-marry-this-guy-he-aint-worth-it-calling">boyfriend thought they were a scam</a>, he said, "&#8217;Don't marry this guy, he ain't worth it." He has also highlighted the importance of tackling debt,&nbsp;<a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45187836/dave-ramsey-blasts-budget-slackers-who-bail-on-401ks-during-market-turmoil-shortterm-temper-tantrums" target="_blank" rel="noreferrer noopener">putting extra cash&nbsp;into a 401(k)&nbsp;</a>and Roth IRA, and investing in broad‑based mutual funds that compound over decades.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next: <a href="https://www.benzinga.com/tech/25/05/45483858/elon-musk-asked-his-date-do-you-ever-think-about-electric-cars-the-date-flopped-but-his-obsession-sparked-a-400-billion-journey">Elon Musk Asked His Date, &#8216;Do You Ever Think About Electric Cars?&#8217; — The Date Flopped, But His Obsession Sparked A $400 Billion Journey</a>
Image via Shutterstock

Personal Finance

General

Her Husband Lost $270K In A Crypto Scam And Lied About It—Dave Ramsey's Advice Pulled No Punches

GILT

Gilat Satellite Networks shares are trading lower after the company reported a Q1 revenue miss.

NVAX

Novavax shares are trading higher after the company provided FY25, 2026, and 2027 R&D and SG&A expense guidance.

CRGY

Crescent Energy Appoints Joey Hall As COO, Effective June 2, 2025

Biotech

CTMX

CytomX Therapeutics Doses First Patient In Combination Arm Of Phase 1 Study Of CX-801 Plus KEYTRUDA In Patients With Metastatic Melanoma

<a href="https://www.globenewswire.com/Tracker?data=7t34k9w8GVCUjvO8I9bhA9sPUlDEGhJtpvOU1ABAO6H-GeKj60HFb42-EYWwRgc2TGP4u0eIf8760OZ0AJOLfVQUSPLllaz_6xHzjTYjPVkKFVpCOHjA_aXAyTPgIdO0hJCF0eqSRDRMC-aZXXh9KpL7kboOsymUwU5GVZtK0KMD2rAwSI2K3_RHFWb3hbp0P9ZIiUbT8PxfFKn6yDmlPY53vk90qzYW0mlg8pr47a6XwI090Aw-UG_53qGEad3Cwrf9LRZtKxQxGqgbK4ceryTKHGgHrWCFlyFpauzgIHo=">MARKER THERAPEUTICS, INC.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,&nbsp;today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT.

MRKR

Marker Therapeutics To Highlight Multi-Antigen Recognizing-T Cells In High-Profile Panel On CAR-T Cell Therapies

<h3>Gainers</h3>
<ul>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares rose 7.2% to $0.01 during Monday's pre-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) shares moved upwards by 7.0% to $1.07. The market value of their outstanding shares is at $33.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares increased by 6.12% to $0.98. The market value of their outstanding shares is at $18.7 million. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) stock increased by 6.03% to $1.23. The market value of their outstanding shares is at $250.3 million. </li>
<li>Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares moved upwards by 5.3% to $6.55. The company's market cap stands at $762.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock decreased by 14.2% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $20.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) stock decreased by 10.24% to $6.97. The market value of their outstanding shares is at $173.4 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock decreased by 9.78% to $0.36. The market value of their outstanding shares is at $10.1 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock declined by 7.84% to $0.1. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock fell 7.48% to $0.99. The company's market cap stands at $8.5 million. </li>
<li>Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) stock decreased by 6.77% to $11.44. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENN

GNLN

GORV

LOBO

LVWR

SWIM

TOPW

11 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 110.1% to $0.02 during Monday's pre-market session. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 78.48% to $5.41. The market value of their outstanding shares is at $2.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 41.66% to $1.87. The company's market cap stands at $10.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 34.84% to $0.01. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) stock increased by 32.59% to $1.79. The company's market cap stands at $64.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares moved upwards by 25.04% to $1.5. The market value of their outstanding shares is at $20.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 17.6% to $2.01 during Monday's pre-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 14.78% to $6.69. The market value of their outstanding shares is at $44.0 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock fell 11.12% to $0.8. The company's market cap stands at $64.7 million. The company's, H1 earnings came out 2 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 10.51% to $4.09. The market value of their outstanding shares is at $22.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock fell 8.78% to $3.64. The market value of their outstanding shares is at $19.4 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 7.89% to $0.21. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMP

BCLI

FBRX

HCTI

IMAB

KLTO

LPCN

MYNZ

PLRZ

PTIX

STSS

SXTC

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock rose 41.2% to $1.44 during Monday's pre-market session. The market value of their outstanding shares is at $15.8 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares moved upwards by 11.31% to $0.17. The market value of their outstanding shares is at $5.2 million. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares moved upwards by 8.41% to $1.03. The company's market cap stands at $3.2 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock increased by 8.33% to $0.24. The company's market cap stands at $6.9 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) shares rose 8.3% to $0.8. The company's market cap stands at $40.1 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) stock rose 8.18% to $1.19. The company's market cap stands at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares declined by 13.4% to $5.6 during Monday's pre-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares fell 11.43% to $2.17. The market value of their outstanding shares is at $11.2 million. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) shares declined by 9.31% to $2.34. The company's market cap stands at $268.6 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock declined by 8.4% to $0.12. The market value of their outstanding shares is at $17.6 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock decreased by 8.26% to $0.56. The company's market cap stands at $3.3 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares decreased by 7.53% to $0.43. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

ATXG

CAPS

CLIR

HKPD

LICN

RYDE

SGBX

VSTE

XPON

12 Industrials Stocks Moving In Monday's Pre-Market Session

Press Releases

ImmunityBio to Host Investor Day

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

Comments

ImmunityBio

ImmunityBio (IBRX) 옵션

ImmunityBio (NASDAQ:IBRX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌